Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7713617 | 0.84 | ALDH1A1 (0.46) | TSHREPHX2NAAAFAAHALDH1A1 | |
| SCHEMBL27661517 | 0.82 | PRMT1 (0.52) | TSHREPHX2LMNANAAA | |
| SCHEMBL27331406 | 0.82 | PRMT1 (0.52) | TSHREPHX2LMNANAAA | |
| SCHEMBL27539725 | 0.81 | NAAA (0.61) | TSHREPHX2LMNANAAARECQL | |
| SCHEMBL2944837 | 0.81 | EPHX2 (0.38) | TSHREPHX2LMNARECQL | |
| SCHEMBL11232047 | 0.80 | NAAA (0.61) | EPHX2NAAAFAAHMEN1KMT2A | |
| SCHEMBL11619047 | 0.80 | NAAA (0.61) | EPHX2NAAAFAAHMEN1KMT2A | |
| SCHEMBL21099687 | 0.80 | NAAA (0.61) | EPHX2NAAAFAAHMEN1KMT2A | |
| SCHEMBL27457489 | 0.80 | NAAA (0.65) | TSHREPHX2LMNANAAARECQL | |
| SCHEMBL27501222 | 0.80 | NAAA (0.65) | TSHREPHX2LMNANAAARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737161-B2 | Condensed furan compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090156803-A1 | Condensed furan compounds | KAWAGUCHI TAKAYUKI | 2009-06-18 | — | — | US | disclosed |
| US-7514449-B2 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7375119-B2 | Amide type carboxamide derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20060287329-A1 | Amide type carboxamide derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-12-21 | — | — | US | disclosed |
| EP-1666455-A1 | AMIDE TYPE CARBOXAMIDE DERIVATIVE | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20060094724-A1 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1582521-A1 | FUSED FURAN COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287329-A1 | Amide type carboxamide derivative | F12, F11, F13A1 | TSHR 490/4885EPHX2 2962/4885LMNA 1114/4885 |
| US-20090156803-A1 | Condensed furan compounds | F2, F12, F11 | TSHR 3368/4885EPHX2 1001/4885LMNA 832/4885 |
| US-20060094724-A1 | Fused furan compound | F2, F12, F11 | TSHR 3045/4885EPHX2 873/4885LMNA 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.